Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Optive Plus is a multi-action artificial tear formulation developed by Allergan (now AbbVie) for the treatment of dry eye disease (DED). It is a lipid-containing emulsion that combines the lubricating properties of carboxymethylcellulose (CMC) and glycerin with the osmoprotective effects of L-carnitine and erythritol. A key feature of the formulation is the inclusion of highly pure castor oil, delivered via a polysorbate-80 micellar system, which replenishes the tear film's lipid layer to reduce tear evaporation. The product is specifically designed to address hyperosmolarity and lipid deficiency, making it particularly effective for patients with evaporative dry eye or mixed-deficiency dry eye. It is typically preserved with PURITE, which breaks down into natural tear components upon contact with the eye.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Optive Plus.